Table 2. Clinical and Laboratory Findings of Patients With COVID-19.
| Characteristic | No. (%) | P value | |
|---|---|---|---|
| Cohorts with COVID-19 clusters (n = 228) | Cohorts without COVID-19 clusters (n = 175) | ||
| Men | 204 (89) | 114 (64) | <.001 |
| Women | 24 (11) | 61 (35) | |
| Time in training, median (IQR), wk | 4 (2-5) | 0 (0-2) | <.001 |
| Time symptomatic before presentation, median (IQR), d | 2 (1-3) | 1 (0-3) | .37 |
| Ct, median (IQR) | <.001 | ||
| Overall | 25.0 (19.7-31.1)a | 35.4 (25.6-37.8)b | |
| Symptomatic patients | 21.1 (18.4-26.6)c | 22.9 (18.3-34.4)d | .36 |
| Asymptomatic patients | 30.1 (25.9-32.8)e | 36.5 (32.6-38.0)f | <.001 |
| Symptomatic patients | 146 (64) | 53 (30) | <.001 |
| Symptoms | |||
| Chest pain | 13 (9) | 6 (11) | .60 |
| Dyspnea | 33 (23) | 4 (8) | .02 |
| Cough | 56 (38) | 13 (25) | .07 |
| Headache | 82 (56) | 19 (36) | .01 |
| Fever | 40 (27) | 5 (9) | .01 |
| Chills | 40 (27) | 6 (11) | .02 |
| Nausea | 11 (8) | 6 (11) | .40 |
| Vomiting | 2 (12) | 1 (2) | .79 |
| Diarrhea | 11 (8) | 1 (2) | .14 |
| Myalgia | 67 (46) | 6 (11) | <.001 |
| Sore throat | 53 (36) | 14 (26) | .19 |
| Anosmia | 33 (23) | 5 (8) | .03 |
| Runny nose | 28 (19) | 3 (6) | .02 |
| Congestion | 14 (10) | 13 (25) | .01 |
| Symptoms, No. | |||
| 0 | 82 (36) | 122 (70) | <.001 |
| 1 | 35 (15) | 23 (13) | |
| 2 | 26 (11) | 18 (10) | |
| 3 | 29 (13) | 5 (3) | |
| 4 | 18 (8) | 6 (3) | |
| 5 | 12 (5) | 1 (1) | |
| 6 | 12 (5) | 0 | |
| 7 | 8 (4) | 0 | |
| 8 | 6 (3) | 0 | |
Abbreviations: COVID-19, coronavirus disease 2019; Ct, cycle threshold; IQR, interquartile range.
a
Based on 178 of 228 available observations (78%).
b
Based on 158 of 175 available observations (90%).
c
Based on 108 of 146 available observations (74%).
d
Based on 45 of 53 available observations (85%).
e
Based on 70 of 82 available observations (85%).
f
Based on 113 of 122 (93%) available observations.